SNDX vs TECX: fair value comparison
Syndax Pharmaceuticals, Inc. and Tectonic Therapeutic, Inc. · Updated 2026-10-19
SNDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TECX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SNDX currently ranks higher by quality score.
| SNDX | TECX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $12.90 | $20.65 |
| 12-month range | $12.90–$25.15 | $16.44–$37.93 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #269 of 301 Healthcare | #271 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| Margin trend | Stable | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: SNDX fair value analysis · TECX fair value analysis